You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Diagnostic utility of ERG immunostaining in dermatofibroma: be aware of ERG expression in cellular neurothekeoma
  1. Fleur Cordier1,2,
  2. Liesbeth Ferdinande1,
  3. Jo Van Dorpe1,2,
  4. David Creytens1,2
  1. 1 Department of Pathology, Ghent University Hospital, Ghent University, Ghent, Belgium
  2. 2 CRIG, Cancer Research Institute Ghent, Ghent University Hospital, Ghent University, Ghent, Belgium
  1. Correspondence to Dr David Creytens; david.creytens{at}uzgent.be

https://doi.org/10.1136/jcp-2024-209913

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We have read with great interest the paper by Yamada et al,1 which demonstrates frequent ERG immunostaining positivity in dermatofibroma (fibrous histiocytoma) using a monoclonal antibody against the N-terminus of the ERG molecule (ACR421C;1:100; Biocare). In this study, all cases of dermatofibrosarcoma protuberans and other types of cutaneous neoplasms (including myxofibrosarcoma, undifferentiated pleomorphic sarcoma, atypical fibroxanthoma, malignant melanoma, melanocytic nevus, neurofibroma, schwannoma, angioleiomyoma and pilar leiomyoma) were negative for ERG. However, cellular neurothekeomas were not included in this study.

    Cellular neurothekeoma, formerly considered to be a nerve sheath tumour, is a relatively rare benign dermal neoplasm with conflicting opinions regarding its histogenetic origin. They typically occur on the head, neck and upper body regions of young adults.2 3 Prompted by an index case of a cellular neurothekeoma …

    View Full Text

    Footnotes

    • Handling editor Vikram Deshpande.

    • Contributors FC performed the writing of the paper. LF and JVD performed the review of the paper. DC performed the study concept, design and writing of the paper. All authors read and approved the final paper.

    • Funding David Creytens was financially supported by a senior clinical research fellowship from the Research Foundation Flanders (1800725N). Other authors received no financial support for the research, authorship, and/or publication of this article.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.